Preoperative intensity-modulated chemoradiotherapy with simultaneous integrated boost in rectal cancer: five-year follow-up results of a phase II study

1Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30: 4558-65. doi: 10.1200/ JCO.2012.42.8771 Gérard JP Azria D Gourgou-Bourgade S Martel-Lafay I Hennequin C Etienne PL et al Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer J Clin Oncol 2012 30 4558 65 10.1200/JCO.2012.42.8771Open DOISearch in Google Scholar

2Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-87. doi: 10.1016/S1470-2045(12)70187-0 Rödel C Liersch T Becker H Fietkau R Hohenberger W Hothorn T et al Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial Lancet Oncol 2012 13 679 87 10.1016/S1470-2045(12)70187-0Open DOISearch in Google Scholar

3O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014; 32: 1927-34. doi: 10.1200/ JCO.2013.53.7753 O’Connell MJ Colangelo LH Beart RW Petrelli NJ Allegra CJ Sharif S et al Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04 J Clin Oncol 2014 32 1927 34 10.1200/JCO.2013.53.7753Open DOISearch in Google Scholar

4Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 29-42. doi: 10.1016/S1470-2045(20)30555-6 Bahadoer RR Dijkstra EA van Etten B Marijnen CAM Putter H Kranenbarg EM et al Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial Lancet Oncol 2021 22 29 42 10.1016/S1470-2045(20)30555-6Open DOISearch in Google Scholar

5Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol 2010; 5: 17. doi: 10.1186/1748-717X-5-17 Arbea L Ramos LI Martínez-Monge R Moreno M Aristu J Intensity-modulated radiation therapy (IMRT) vs 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol 2010 5 17 10.1186/1748-717X-5-17284559320187944Open DOISearch in Google Scholar

6Guerrero Urbano MT, Henrys AJ, Adams EJ, Norman AR, Bedford JL, Harrington KJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 2006; 65: 907-16. doi: 10.1016/j. ijrobp.2005.12.056 Guerrero Urbano MT Henrys AJ Adams EJ Norman AR Bedford JL Harrington KJ et al Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels Int J Radiat Oncol Biol Phys 2006 65 907 16 10.1016/j.ijrobp.2005.12.05616751073Open DOISearch in Google Scholar

7Engels B, De Ridder M, Tournel K, Sermeus A, De Coninck P, Verellen D, et al. Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel. Int J Radiat Oncol Biol Phys 2009; 74: 1476-80. doi: 10.1016/j.ijrobp.2008.10.017 Engels B De Ridder M Tournel K Sermeus A De Coninck P Verellen D et al Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel Int J Radiat Oncol Biol Phys 2009 74 1476 80 10.1016/j.ijrobp.2008.10.01719231097Open DOISearch in Google Scholar

8Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 2011; 6: 63. doi: 10.1186/1748-717X-6-63 Mok H Crane CH Palmer MB Briere TM Beddar S Delclos ME et al Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma Radiat Oncol 2011 6 63 10.1186/1748-717X-6-63312160621651775Open DOISearch in Google Scholar

9Li JL, Ji JF, Cai Y, Li XF, Li YH, Wu H, et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial. Radiother Oncol 2012; 102: 4-9. doi: 10.1016/j.radonc.2011.07.030 Li JL Ji JF Cai Y Li XF Li YH Wu H et al Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial Radiother Oncol 2012 102 4 9 10.1016/j.radonc.2011.07.03021903285Open DOISearch in Google Scholar

10Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme G, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol 2014; 110: 155-9. doi: 10.1016/j. radonc.2013.10.026 Engels B Platteaux N Van den Begin R Gevaert T Sermeus A Storme G et al Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome Radiother Oncol 2014 110 155 9 10.1016/j.radonc.2013.10.02624239243Open DOISearch in Google Scholar

11Hernando-Requejo O, López M, Cubillo A, Rodriguez A, Ciervide R, Valero J, et al. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol 2014; 190: 515-20. doi: 10.1007/s00066-014-0650-0 Hernando-Requejo O López M Cubillo A Rodriguez A Ciervide R Valero J et al Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation Strahlenther Onkol 2014 190 515 20 10.1007/s00066-014-0650-0Open DOISearch in Google Scholar

12Picardi V, Macchia G, Guido A, Giaccherini L, Deodato F, Farioli A, et al. Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study. Clin Colorectal Cancer 2017; 16: 16-22. doi: 10.1016/j. clcc.2016.06.004 Picardi V Macchia G Guido A Giaccherini L Deodato F Farioli A et al Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study Clin Colorectal Cancer 2017 16 16 22 10.1016/j.clcc.2016.06.004Open DOISearch in Google Scholar

13Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15: 1245-53. doi: 10.1016/S1470-2045(14)70377-8 Hong YS Nam BH Kim KP Kim JE Park SJ Park YS et al Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial Lancet Oncol 2014 15 1245 53 10.1016/S1470-2045(14)70377-8Open DOISearch in Google Scholar

14Zhu J, Liu F, Gu W, Lian P, Sheng W, Xu J, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol 2014; 9: 70. doi: 10.1186/1748-717X-9-70 Zhu J Liu F Gu W Lian P Sheng W Xu J et al Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study Radiat Oncol 2014 9 70 10.1186/1748-717X-9-70398473324606870Open DOISearch in Google Scholar

15Hong TS, Moughan J, Garofalo MC, Bendell J, Berger AC, Oldenburg NB, et al. NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015; 93: 29-36. doi: 10.1016/j.ijrobp.2015.05.005 Hong TS Moughan J Garofalo MC Bendell J Berger AC Oldenburg NB et al NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer Int J Radiat Oncol Biol Phys 2015 93 29 36 10.1016/j.ijrobp.2015.05.005454062826163334Open DOISearch in Google Scholar

16But-Hadzic J, Anderluh F, Brecelj E, Edhemovic I, Secerov-Ermenc A, Hudej R, et al. Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost: a phase 2 trial. Int J Radiat Oncol 2016; 96: 1003-10. doi: 10.1016/j.ijrobp.2016.08.031 But-Hadzic J Anderluh F Brecelj E Edhemovic I Secerov-Ermenc A Hudej R et al Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost: a phase 2 trial Int J Radiat Oncol 2016 96 1003 10 10.1016/j.ijrobp.2016.08.03127727065Open DOISearch in Google Scholar

17But-Hadzic J, Velenik V. Preoperative intensity-modulated chemoradiation therapy with simultaneous integrated boost in rectal cancer: 2-year follow-up results of phase II study. Radiol Oncol 2018; 52: 23-29. doi: 10.1515/ raon-2018-0007 But-Hadzic J Velenik V Preoperative intensity-modulated chemoradiation therapy with simultaneous integrated boost in rectal cancer: 2-year follow-up results of phase II study Radiol Oncol 2018 52 23 29 10.1515/raon-2018-0007583907829520202Open DOISearch in Google Scholar

18Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4. doi: 10.1245/s10434-010-0985-4 Edge SB Compton CC The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 2010 17 1471 4 10.1245/s10434-010-0985-420180029Open DOISearch in Google Scholar

19Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23. doi: 10.1007/s003840050072 Dworak O Keilholz L Hoffmann A Pathological features of rectal cancer after preoperative radiochemotherapy Int J Colorectal Dis 1997 12 19 23 10.1007/s0038400500729112145Open DOISearch in Google Scholar

20Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) v5.0.; 2017. [cited 2021 Feb 04]. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf Cancer Institute N Common Terminology Criteria for Adverse Events (CTCAE) v5.0 2017 [cited 2021 Feb 04]. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdfSearch in Google Scholar

21Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76. doi: 10.1093/jnci/85.5.365 Aaronson NK Ahmedzai S Bergman B Bullinger M Cull A Duez NJ et al The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 1993 85 365 76 10.1093/jnci/85.5.3658433390Open DOISearch in Google Scholar

22van der Hout A, Neijenhuijs KI, Jansen F, van Uden-Kraan CF, Aaronson NK, Groenvold M, et al. Measuring health-related quality of life in colorectal cancer patients: systematic review of measurement properties of the EORTC QLQ-CR29. Support Care Cancer 2019; 27: 2395-412. doi: 10.1007/ s00520-019-04764-7 van der Hout A Neijenhuijs KI Jansen F van Uden-Kraan CF Aaronson NK Groenvold M et al Measuring health-related quality of life in colorectal cancer patients: systematic review of measurement properties of the EORTC QLQ-CR29 Support Care Cancer 2019 27 2395 412 10.1007/s00520-019-04764-7Open DOISearch in Google Scholar

23Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. European Organisation for Research and Treatment of Cancer; 2001. [cited 2021 Feb 04]. Available at https://abdn.pure.elsevier.com/en/publications/eortc-qlq-c30-scoring-manual-3rd-edition Fayers P Aaronson NK Bjordal K Groenvold M Curran D Bottomley A EORTC QLQ-C30 Scoring Manual. European Organisation for Research and Treatment of Cancer; 2001 [cited 2021 Feb 04]. Available at https://abdn.pure.elsevier.com/en/publications/eortc-qlq-c30-scoring-manual-3rd-editionSearch in Google Scholar

24Hanna CR, Slevin F, Appelt A, Beavon M, Adams R, Arthur C, et al. Intensity-modulated radiotherapy for rectal cancer in the UK in 2020. Clin Oncol 2021; 33: 214-23. doi: 10.1016/j.clon.2020.12.011 Hanna CR Slevin F Appelt A Beavon M Adams R Arthur C et al Intensity-modulated radiotherapy for rectal cancer in the UK in 2020 Clin Oncol 2021 33 214 23 10.1016/j.clon.2020.12.011Open DOISearch in Google Scholar

25Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-65. doi: 10.1200/JCO.2009.25.8541 Fernández-Martos C Pericay C Aparicio J Salud A Safont M Massuti B et al Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study J Clin Oncol 2010 28 859 65 10.1200/JCO.2009.25.8541Open DOISearch in Google Scholar

26Tey J, Leong CN, Cheong WK, Sze TG, Yong WP, Tham IWK, et al. A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer. J Cancer 2017; 8: 3114-21. doi: 10.7150/jca.21237 Tey J Leong CN Cheong WK Sze TG Yong WP Tham IWK et al A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer J Cancer 2017 8 3114 21 10.7150/jca.21237Open DOISearch in Google Scholar

27Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radio-sensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J 2006; 47: 693-700. Velenik V Anderluh F Oblak I Strojan P Zakotnik B Capecitabine as a radio-sensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial Croat Med J 2006 47 693 700Search in Google Scholar

28Simson DK, Mitra S, Ahlawat P, Saxena U, Sharma MK, Rawat S, et al. Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer – Toxicities and response assessment. Cancer Manag Res 2018; 10: 519-26. doi: 10.2147/CMAR.S142076 Simson DK Mitra S Ahlawat P Saxena U Sharma MK Rawat S et al Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer – Toxicities and response assessment Cancer Manag Res 2018 10 519 26 10.2147/CMAR.S142076Open DOISearch in Google Scholar

29Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010; 5: 88. doi: 10.1186/1748-717X-5-88 Velenik V Oblak I Anderluh F Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer Radiat Oncol 2010 5 88 10.1186/1748-717X-5-88Open DOISearch in Google Scholar

30Garofalo M, Moughan J, Hong T, J.Bendell, A.Berger, F.Lerma, et al. RTOG 0822: a phase II study of preoperative (PREOP) chemoradiotherapy (CRT) utilizing IMRT in combination with capecitabine (C) and oxaliplatin (O) for patients with locally advanced rectal cancer. Int J Radiat Oncol 2011; 81: S3-S4. doi: 10.1016/j.ijrobp.2011.06.008 Garofalo M Moughan J Hong T J Bendell, A.Berger, F.Lerma, et al. RTOG 0822: a phase II study of preoperative (PREOP) chemoradiotherapy (CRT) utilizing IMRT in combination with capecitabine (C) and oxaliplatin (O) for patients with locally advanced rectal cancer Int J Radiat Oncol 2011 81 S3 S4 10.1016/j.ijrobp.2011.06.008Open DOISearch in Google Scholar

31Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014; 32: 1554-62. doi: 10.1200/JCO.2013.54.3769 Fokas E Liersch T Fietkau R Hohenberger W Beissbarth T Hess C et al Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial J Clin Oncol 2014 32 1554 62 10.1200/JCO.2013.54.3769Open DOISearch in Google Scholar

32George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a new surrogate endpoint in rectal cancer clinical trials. Curr Colorectal Cancer Rep 2015; 11: 275-80. doi: 10.1007/s11888-015-0285-2 George TJ Allegra CJ Yothers G Neoadjuvant Rectal (NAR) Score: a new surrogate endpoint in rectal cancer clinical trials Curr Colorectal Cancer Rep 2015 11 275 80 10.1007/s11888-015-0285-2Open DOISearch in Google Scholar

33Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-44. doi: 10.1016/S1470-2045(10)70172-8 Maas M Nelemans PJ Valentini V Das P Rödel C Kuo LJ et al Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 2010 11 835 44 10.1016/S1470-2045(10)70172-8Open DOISearch in Google Scholar

34Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40. doi: 10.1056/NEJMoa040694 Sauer R Becker H Hohenberger W Rödel C Wittekind C Fietkau R et al Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 2004 351 1731 40 10.1056/NEJMoa04069415496622Open DOISearch in Google Scholar

35Urso E, Serpentini S, Pucciarelli S, De Salvo GL, Friso ML, Fabris G, et al. Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. Eur J Surg Oncol 2006; 32: 1201-8. doi: 10.1016/j.ejso.2006.07.003 Urso E Serpentini S Pucciarelli S De Salvo GL Friso ML Fabris G et al Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer Eur J Surg Oncol 2006 32 1201 8 10.1016/j.ejso.2006.07.00316872799Open DOISearch in Google Scholar

36Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-23. doi: 10.1056/NEJMoa060829 Bosset JF Collette L Calais G Mineur L Maingon P Radosevic-Jelic L et al Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 2006 355 1114 23 10.1056/NEJMoa06082916971718Open DOISearch in Google Scholar

37Velenik V, Secerov-Ermenc A, But-Hadzic J, Zadnik V. Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general slovenian population. Radiol Oncol 2017; 51: 342-50. doi: 10.1515/ raon-2017-0021 Velenik V Secerov-Ermenc A But-Hadzic J Zadnik V Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general slovenian population Radiol Oncol 2017 51 342 50 10.1515/raon-2017-0021561199928959171Open DOISearch in Google Scholar

38Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC Quality of Life Group. EORTC QLQ-C30 Reference Values; 2008. [cited 2021 Feb 04]. Available at https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf Scott NW Fayers PM Aaronson NK Bottomley A de Graeff A Groenvold M et al EORTC Quality of Life Group EORTC QLQ-C30 Reference Values; 2008 [cited 2021 Feb 04]. Available at https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdfSearch in Google Scholar